Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia

Nat Microbiol. 2023 Oct;8(10):1911-1919. doi: 10.1038/s41564-023-01461-4. Epub 2023 Aug 28.

Abstract

Diagnosis and treatment of Plasmodium falciparum infections are required for effective malaria control and are pre-requisites for malaria elimination efforts; hence we need to monitor emergence, evolution and spread of drug- and diagnostics-resistant parasites. We deep sequenced key drug-resistance mutations and 1,832 SNPs in the parasite genomes of 609 malaria cases collected during a diagnostic-resistance surveillance study in Ethiopia. We found that 8.0% (95% CI 7.0-9.0) of malaria cases were caused by P. falciparum carrying the candidate artemisinin partial-resistance kelch13 (K13) 622I mutation, which was less common in diagnostic-resistant parasites mediated by histidine-rich proteins 2 and 3 (pfhrp2/3) deletions than in wild-type parasites (P = 0.03). Identity-by-descent analyses showed that K13 622I parasites were significantly more related to each other than to wild type (P < 0.001), consistent with recent expansion and spread of this mutation. Pfhrp2/3-deleted parasites were also highly related, with evidence of clonal transmissions at the district level. Of concern, 8.2% of K13 622I parasites also carried the pfhrp2/3 deletions. Close monitoring of the spread of combined drug- and diagnostic-resistant parasites is needed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials* / pharmacology
  • Artemisinins* / pharmacology
  • Ethiopia / epidemiology
  • Humans
  • Malaria, Falciparum* / diagnosis
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / epidemiology
  • Plasmodium falciparum / metabolism
  • Protozoan Proteins / genetics
  • Protozoan Proteins / metabolism

Substances

  • Antimalarials
  • Protozoan Proteins
  • artemisinin
  • Artemisinins